Skip to main content
letter
. 2021 Apr 19;35(7):e425–e427. doi: 10.1111/jdv.17250

Figure 1.

Figure 1

(a) A 34‐year‐old female healthcare worker showing a slightly indurated erythematous targetoid patch at the injection‐site reaction of 6 × 4.5 cm diameter, 8 days after the first dose of the BNT162b2 vaccine. (b) Histologic examination shows a superficial and deep perivascular lymphocytic infiltrate (H‐E ×100). (c) Close‐up examination shows dilated vessels, repleted with intraluminal neutrophils. An increased number of eosinophils or mast cells was not present (H‐E ×400).